Top Markets
Coin of the day
AIM ImmunoTech Inc. AIM ImmunoTech Inc.

AIM ImmunoTech Inc.

AIM
Clasificación en acciones #38741
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida,... AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
Precio por acción
$0.2438
Capitalización bursátil
$829.78K
Cambio (1 día)
-5.61%
Cambio (1 año)
-89.93%
País
US
Comercio AIM ImmunoTech Inc. (AIM)

Categoría

Ratio P/B de AIM ImmunoTech Inc. (AIM)
Ratio P/B al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de AIM ImmunoTech Inc., el ratio P/B actual (TTM) es 0. Al final de 2026, el ratio P/B era 0.
Historial del ratio P/B de AIM ImmunoTech Inc. desde 2026 hasta 2026
Ratio P/B al final de cada año
Año Ratio P/B Cambiar
Not enough data for the provided dates.
Ratio P/B de empresas similares o competidoras
Empresa Ratio P/B Diferencia del ratio P/B País
6.2613 -
US
6.3483 -
NL
- -
CH
- -
KR
3.634 -
BE